iarjsIARJSIARJS2789-6102https://doi.org/10.47310/iarjs.2022.v02i02.014Diagnostic Performance Comparison between68Ga PSMA PET/CT and mpMRI in Prostate Cancer PatientsViperSharmaRishabhChadhaBrijenderBackground: The present study was done to compare the Diagnostic performance of 68Ga PSMA PET/CT and mpMRI in prostate cancer patients. Material and Methods: Forty-four patients with suspected PCa on clinical assessment and/or raised serum PSA levels (>4ng/mL) were prospectively recruited. Patient who underwent prostatic biopsy prior to 68Ga-PSMA PET/CT and mpMRI, deranged renal function tests or coagulogram and refused consent were excluded. Forty-four patients underwent 68Ga-PSMA PET/CT and 33 patients underwent mpMRI and biopsy. In total, 68Ga-PSMA PET/CT was done in all 33 patients who underwent biopsy but mpMRI was done in 22 of these only and were included for final analysis. Results: Mean age of patients was 66.61±9.3 years and median PSA level was 13.4 ng/mL (IQR 13.9). Malignancy was detected in 16/33 (48.5%) patients who underwent biopsy. The sensitivity, specificity, PPV, NPV and accuracy of 68Ga-PSMA PET/CT to detect PCa was 81.25%, 88.24%, 86.67%, 83.33% and 84.85% respectively. When PIRADS III-V were considered as positive lesions on mpMRI, the sensitivity, specificity, PPV, NPV and accuracy of mpMRI was 100%, 81.82%, 84.62%, 100% and 90.91% respectively to detect the adenocarcinoma PCa. Substantial agreement was found between 68Ga-PSMA PET/CT and mpMRI findings (kappa value 0.732). Conclusions: There is significant agreement/concordance between 68Ga PSMA PET/CT and mpMRI in suspected PCa cases. 68Ga PSMA PET/CT should be used as a complimentary modality to mpMRI in patients with suspected PCa especially in cases with equivocal findings on mpMRI and high clinical suspicion.